Cholesterol drug appears beneficial for Smith-Lemli-Opitz syndrome
Simvastatin, commonly prescribed for reducing cholesterol, may be effective for treating Smith-Lemli-Opitz syndrome (SLOS), according to a new study from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), part of the National Institutes of Health. The study is the first randomized, double-blinded, placebo-controlled trial of a statin drug for SLOS, a rare genetic disease that currently has no cure or approved treatment.